GSK names head of new r&d centre in China
GlaxoSmithKline (GSK) has appointment of Jingwu Zang to head its new GSK r&d centre in Shanghai, China. His appointment, as senior vice president, will be effective in June.
GlaxoSmithKline (GSK) has appointment of Jingwu Zang to head its new GSK r&d centre in Shanghai, China. His appointment, as senior vice president, will be effective in June.
The centre will focus on research into neurodegeneration with the objective of creating new medicines for such severe disorders as multiple sclerosis, Parkinson's disease, and Alzheimer's disease.
The centre will eventually direct the global discovery and development activities within its therapeutic area, from drug-target identification to late-stage clinical studies, while collaborating with research institutions elsewhere in China and other countries.
Dr Zang, a neurologist and researcher in immunological and neurodegenerative disorders, will lead the scientific activities of the centre and the hiring of staff, which will begin immediately. It is anticipated that over the next decade the centre will become one of the larger r&d facilities within GSK. Dr. Zang will report directly to Moncef Slaoui, chairman, GSK r&d.
Dr Zang was a founding director and a professor at the Instituteof Health Sciencesin Shanghai. The Institute is an affiliate of the Chinese Academy of Sciences and the Shanghai Jiao Tong University School of Medicine. Before that he was research director of the Baylor Multiple Sclerosis Centre, Houston, Texas, where he concentrated on clinical research in multiple sclerosis and neuroimmunology.